Horizon Discovery signed a three-year agreement with the National Human Genome Research Institute and the National Cancer Institute allowing researchers access to its Genesis rAAV gene-editing technology to generate cell lines for basic and translational research. NHGRI and Horizon researchers will develop isogenic disease models of melanoma. NCI will also develop disease models for research and establish a center for excellence in gene editing.

Related Summaries